Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
14 déc. 2023 07h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3...
United States Clinical Trial Data Management Service Market Insights Report 2023-2028 Featuring Prominent Vendors - IQVIA,SYNEOS, ICON and Labcorp
21 nov. 2023 04h38 HE
|
Research and Markets
Dublin, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The "US Clinical Trial Data Management Service Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering. The US...
Global Progressive Supranuclear Palsy Clinical Trial Pipeline Highlights 2022
08 févr. 2023 13h23 HE
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Global Progressive Supranuclear Palsy Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.This...
Global Hemophilia-A Clinical Trial Pipeline Report 2022
02 févr. 2023 13h38 HE
|
Research and Markets
Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Hemophilia A Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.The report Hemophilia A...
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
02 juil. 2019 09h00 HE
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Highlights Key Phase 2b Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018
05 juin 2018 08h30 HE
|
Ritter Pharmaceuticals, Inc.
Additional Data Describes Novel Clinical Symptom Assessment Tool Developed in Phase 2b Trial and to be Used in Upcoming Phase 3 Clinical Trial LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- Ritter...
Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation
17 déc. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...
Sucampo and Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation in Adults With Chronic Idiopathic Constipation
23 oct. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...
Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa
21 oct. 2013 20h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), today announced that its development partner, R-Tech Ueno, Ltd....